A Phase 2 clinical trial (NCT02259621) of neo-adjuvant anti-PD-1 (Nivolumab) in NSCLC supports that increased T cell clonality was associated with reduced percent residual tumor at surgery93. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.